Q-omics provides the consensus-scored ENO1P3 profile across patient tissues and cancer cell-line models. ENO1P3 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ENO1P3 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, ENO1P3 RNA expression shows 9,662 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LUAD, KICH, and PDAC as cancer lineages where ENO1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENO1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENO1P3 survival associations across molecular data types. ENO1P3 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENO1P3 RNA expression–survival associations across cancer types. High ENO1P3 expression shows unfavorable associations in KICH, MESO, UVM, UCS and KIRP, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify LUAD as the clearest survival context for ENO1P3 RNA expression.
This table summarizes ENO1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ENO1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENO1P3 shows lower tumor expression in KICH and KIRP and higher tumor expression in STAD and HNSC. The KICH box plot shows higher ENO1P3 RNA expression in normal versus tumor tissue (log2 FC = −0.025, t-test p < 0.001).
This table shows molecular features associated with ENO1P3 in patient tissues and cancer cell lines. In patient samples, ENO1P3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
